Stilbene Treatment Reduces Stemness Features in Human Lung Adenocarcinoma Model

Vittoria Livraghi1, Alice Grossi1, Anna Scopelliti1

  • 1Department of Molecular Medicine, Immunology and General Pathology Unit, University of Pavia, 27100 Pavia, Italy.

Insights

4,4'-dihydroxy-trans-stilbene (DHS) and resveratrol (RSV) show potential against lung cancer. DHS notably reduced cancer cell proliferation, clonogenicity, and stemness features, suggesting its promise as an anticancer agent.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Lung cancer is a challenging tumor due to aggressive proliferation, metastasis, and cancer stem cells (CSCs).
  • Natural compounds like resveratrol (RSV) are explored for cancer chemoprevention.
  • 4,4'-dihydroxy-trans-stilbene (DHS), an RSV analogue, shows enhanced activity in preclinical models.

Purpose of the Study:

  • To investigate the effects of DHS and RSV on A549 lung cancer cells.
  • To analyze the impact of these stilbenes on cancer stem cell (CSC) features, focusing on the side population (SP) fraction.

Main Methods:

  • Treatment of A549 lung cancer cells with DHS and RSV.
  • Isolation of CSCs via side population (SP) sorting.
  • Analysis of cell cycle progression, clonogenicity, soft agar colony formation, stemness marker expression, and spheroid formation.

Main Results:

  • Both DHS and RSV inhibited cell cycle progression; DHS reduced the S phase, while RSV increased it.
  • DHS treatment led to a 50% reduction in clonogenicity and soft agar colony formation.
  • DHS and RSV decreased stemness marker expression in A549 cells and SP fraction.
  • DHS significantly reduced spheroid formation and SOX2 levels in SP cells more than RSV.

Conclusions:

  • Stilbenes, particularly DHS, impact stemness features in A549 lung cancer cells and their SP fraction.
  • DHS demonstrates potent anticancer effects, including inhibition of proliferation and stemness.
  • DHS shows potential as an anticancer agent, usable alone or in combination therapy for lung cancer.